Subsequent Thromboembolic and Bleeding Events in Patients With Major Bleeding While on Factor Xa Inhibitors

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Major bleeding while on Factor Xa inhibitors (n=5349). Intervention: Factor Xa inhibitor-related major bleeding. Primary outcome: Post-discharge thromboembolic events and bleeding events.

Q: What does this research mean for the field?

Following a major bleeding event on Factor Xa inhibitors, patients experience a time-dependent risk transition where bleeding risk is highest in the first 90 days and thromboembolic risk steadily increases over the subsequent year. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

T Suzuki; Masahiro Yasaka; Fumitaka Wada; Ryotaro Ide; Kota Suzuki; S H U N Kohsaka

doi:10.1253/circrep.cr-26-0099

July 8, 2026Circulation ReportsOpen Access

Subsequent Thromboembolic and Bleeding Events in Patients With Major Bleeding While on Factor Xa Inhibitors

View Full Paper

Ask AI

Bookmark

Share

Key result

After FXa inhibitor major bleeding, thromboembolic risk rises ~65% over 360 days as bleeding risk subsides.

n=5,349

Figures

Why the study?

Management of patients after Factor Xa inhibitor-associated bleeding is challenging because data on the unpredictable sequencing of subsequent bleeding and thromboembolic events are limited.

Key Points

To evaluate the incidence, temporal patterns, and sequencing of bleeding and thromboembolic events in patients who survived major bleeding while receiving factor Xa inhibitors.
Retrospective cohort study using the Japanese hospital claims database (Medical Data Vision) between 2010 and 2023, identifying 5,349 adults (≥18 years) hospitalized for factor Xa inhibitor-associated major bleeding.
Tracked post-discharge outcomes across four 90-day intervals up to 360 days in patients followed for at least 360 days or who died within 360 days.
Calculated event rates per 100 person-years with 95% confidence intervals for bleeding and thromboembolic complications (acute coronary syndrome, stroke, systemic embolism, venous thromboembolism, and acute limb ischemia) using ICD-10 codes.
Subsequent bleeding event rates were highest during the first 90 days post-discharge at 42.2 per 100 person-years, progressively declining to 18.6 per 100 person-years by days 271–360.
Thromboembolic event rates exhibited an inverse temporal trajectory, steadily increasing from 17.3 per 100 person-years during the first 90 days to 28.6 per 100 person-years during days 271–360.

Study Design

Type

Cohort (n=5,349)

Structured PICO

P

Population

5,349 adult patients (median age 80 years, 37.6% female) who survived hospitalization for Factor Xa inhibitor-related major bleeding, followed for up to 360 days post-discharge.

O

Outcome

Post-discharge thromboembolic events (acute coronary syndrome, stroke, venous sinus thrombosis, systemic embolism, venous thromboembolism, and acute limb ischemia) and bleeding events up to 360 dayshard clinical

Patients surviving Factor Xa inhibitor-related major bleeding experience a dynamic risk transition, with bleeding risk highest in the first 90 days and thromboembolic risk steadily increasing thereafter, highlighting the need for time-dependent anticoagulation management strategies.

Limitations

Focusing on patients surviving index hospitalization may underestimate event rates
Reliance on the MDV database, with monthly event timing, limited clinical variables, and no cross-institutional linkage may have introduced selection bias
ICD-10-based identification could not distinguish bleeding severity or site concordance with the index event
Could not allow reliable comparison between patients who did and did not resume anticoagulation
Reliance on the MDV database, with monthly event timing, limited clinical variables, and no cross-institutional linkage, may have introduced selection bias and limited generalizability

Implication

Supports time-dependent monitoring after Factor Xa inhibitor bleeding; leaves optimal resumption timing open for randomized trials.

Abstract

Background: Management of patients after bleeding associated with Factor Xa inhibitors (FXa-I) remains challenging due to limited available data on unpredictable sequencing of bleeding and thromboembolic events. Methods and Results: This cohort study identified 5,349 patients with FXa-I-related major bleeding. During the 360-day follow-up, bleeding events were highest in the first 90 days (42.2 per 100 person-years), declining to 18.6 by days 271–360. Conversely, thromboembolic events showed a reverse pattern, increasing from 17.3 to 28.6. Conclusions: Patients surviving FXa-I-related bleeding experience a risk transition from bleeding to thromboembolic risk, suggesting the need for time-dependent management strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suzuki et al. (2026) conducted a cohort in Major bleeding while on Factor Xa inhibitors (n=5,349). Factor Xa inhibitor-related major bleeding was evaluated on Post-discharge thromboembolic events and bleeding events. In patients surviving Factor Xa inhibitor-related major bleeding, bleeding risk was highest in the first 90 days (42.2 per 100 person-years) and declined, while thromboembolic risk increased from 17.3 to 28.6 per 100 person-years over 360 days.

synapsesocial.com/papers/6a5090576eeac72a437a186a https://doi.org/10.1253/circrep.cr-26-0099

View Full Paper

Ask AI

Bookmark

Share

Subsequent Thromboembolic and Bleeding Events in Patients With Major Bleeding While on Factor Xa Inhibitors

Figures

Key Points

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Subsequent Thromboembolic and Bleeding Events in Patients With Major Bleeding While on Factor Xa Inhibitors

Figures

Key Points

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Circulation Reports

Keep reading

More related papers

More from Circulation Reports